Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids

Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids

This case report presents a rare occurrence of adrenal insufficiency induced by Zytiga (abiraterone acetate) in a patient with high-risk localized prostatic adenocarcinoma. Abiraterone acetate is a potent, selective and irreversible CYP17A1 inhibitor and is commonly used in the treatment of prostate...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahmed S. Mohamed, Ahmad R. Awwad, Angel Ann Chacko, Shraboni Dey, Brianna Braithwaite, Ruchi Bhuju, Sameh Elias
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Current Oncology
Subjects:
abiraterone acetate
adrenal insufficiency
prostate cancer
mineralocorticoid excess syndrome
prednisolone
CYP17A1
Online Access:https://www.mdpi.com/1718-7729/32/3/156
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/3/156

Similar Items